Compare Adobe Systems Inc (ADBE) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adobe Systems Inc vs Incyte Corporation — how do they compare? Adobe Systems Inc trades at $260.34 (market cap $102.85B), while Incyte Corporation trades at $120.94 (market cap $24.48B). The key difference: Adobe Systems Inc is far larger — about 4.2× Incyte Corporation's market cap, and Incyte Corporation is trading nearer its 52-week high, Adobe Systems Inc nearer its low. Which is the better fit depends on your goals.
| ADBE | INCY | |
|---|---|---|
Market Cap | $102.85B | $24.48B |
Volume | 5,187,646 | — |
Sector | Technology | Health |
52-Week High | $367.46 | $129.93 |
52-Week Low | $193.41 | $81.66 |
Enterprise Value | $104.29B | $19.98B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adobe (ADBE) trades at $261.85, down 0.71% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company demonstrates strong fundamentals with 2025 revenue of $23.77B and net income of $7.13B, achieving a 29.99% profit margin. Recent quarters show consistent earnings beats, with Q1 2026 EPS of $5.96 exceeding expectations. However, the stock faces headwinds from AI competition concerns and a recent 52-week low, creating a divergence between strong financial performance and market sentiment.
Adobe presents a compelling value opportunity with a P/E of 14.8 below historical averages, supported by robust cash flow generation and double-digit revenue growth. Key risks include AI disruption threats to traditional software models and ongoing leadership transition concerns. With 49.2% analyst buy ratings and a consensus price target of $248.86, the stock appears undervalued despite near-term volatility, offering potential for recovery as AI integration benefits materialize.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adobe Systems Inc
Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.
Read more on ADBE →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
